Home > Our Doctors > Find a Doctor

Select Physicians to compare
Photo of Michael Dabrow D.O. FACOI

Michael B Dabrow D.O. FACOI , F.A.C.P.

Request an Appointment

Need help deciding?
Contact 1.866.CALL.MLH or
484.580.1000 for assistance.

Medical Group:

Main Line Oncology/Hematology

Primary Office:

Cancer Center of Paoli Hospital
255 West Lancaster Avenue
Paoli, PA  19301

Office Phone: 484.565.1600
Specialties Accepting New Patients
Hematology/Oncology
  Board Certified in 1991
Yes
Oncology
  Board Certified in 1990
Yes
Internal Medicine
  Board Certified in 1990
No

Age: 56      Gender: M
Years in practice: 23
Main Line HealthCare Physician

Areas of Clinical Interest: Advanced treatment for all cancer diagnoses, including:
- Breast Cancer
- Senior Oncology
- Gynecological Cancers
- Genitourinary Cancers

Medical School:
Kansas City University of Medicine and Bioscience

Internship:
Detroit Osteopathic Hospital

Residency:
Detroit Osteopathic Hospital

Fellowship:
Fox Chase Cancer Center/Temple University Hospital

Primary Affiliation:  Paoli Hospital

* Members of the Main Line Health medical staff are affiliated with Bryn Mawr Hospital, Lankenau Medical Center, Paoli Hospital and Riddle Hospital.

Main Line Oncology/Hematology   (view other physicians at this practice)

Office Information

Location:
Cancer Center of Paoli Hospital
255 West Lancaster Avenue
Paoli, PA  19301

TEL: 484.565.1600 FAX: 610.647.2006
View Map | Get Directions

Access Information:
Public Transportation, Handicap Access

hours icon Hours: Weekdays
 
Location:
Main Line Health Center at Exton Square
154 Exton Square Parkway
Exton, PA  19341

TEL: 484.565.1600 FAX: 610.647.2006
View Map | Get Directions

hours icon Hours: Weekdays
 
Main Line Oncology/Hematology
255 West Lancaster Avenue
Paoli, PA  19301

TEL: 484.565.1600 FAX: 610.647.2006

View Map | Get Directions

Access Information:
Public Transportation, Handicap Access

Hours:Weekdays

Main Line Oncology/Hematology
154 Exton Square Parkway
Exton, PA  19341

TEL: 484.565.1600 FAX: 610.647.2006

View Map | Get Directions

Hours:Weekdays



Statement of Practice Philosophy

To provide the highest quality treatment possible in a supportive, caring environment, utilizing the most effective and innovative therapies, while focused on each individual's special needs and goals of care.

Titles

Academic Titles:
Adjunct Associate Member, Fox Chase Cancer Center
Associate Member, LIMR

Clinical/Dept Titles:

Medical Director, Cancer Center at Paoli Hospital
Attending Physician

Recent Clinical Studies Published

Wilkins-Childs JC, Dabrow MB, Freed N. Sudden onset of a febrile illness in a female with hemochromatosis. Infect Med 12(3):142-144 (1995).

 

Dabrow MB, Antoniades J. Sequential adjuvant CMF Chemotherapy followed by radiotherapy in the treatment of early-stage breast cancer: The Lankenau Hospital Experience. The Breast Journal 3:15-18 (1997).

Dabrow MB, Francesco MR, McBrearty FX, Caradonna S. Effects of Platelet derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncology 71:29-37 (1998).

Dabrow MB, Francesco MR, Gilman PB, Cantor R, Rose L, Meyer TJ. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastitic non-small cell lung cancer. Cancer Invest 21:517-525 (2003).

Langer CJ, Godfrey S, Richter M, Dabrow M, Rosenblum N. Durable complete remission in recurrent metastatic squamous cell carcinoma of the cervix after treatment with bleomycin, ifosfamide and carboplatin. Proc ASCO 14:796 (1995).

Dabrow MB, Gilman PB, Meyer TJ, Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer. Proc ASCO 18:1930 (1999).

Desnoyers R, Fava T, Dabrow M, Mitchell EP, Weinberg DS, Waldman SA. Guanylyl cyclase C (GCC) is a specific biomarker that may be useful for postoperative surveillance of patients with colorectal cancer. Proc ASCO 19:1005 (2000).

Olander E, Shields N, Gilman P, Olander E, Dickinson S, Atassi S, Mushlin J, Schneider A, Gilman P. The impact of breast cancer risk assessment and education for women at average and moderately increased risk. Proc ASHG 67:377 (2000).

Bardakjian T, Shields N, Gilman P, Olander E, Dickinson S, Atassi S, Mushlin J, Schneider A, Dabrow M. The impact of genetic counseling/testing for breast and ovarian cancer in a free and anonymous community program. Proc ASHG 67:395 (2000)

Atassi S, Dabrow M, Olander E, Bardakjian T, Mushlin J, Shields N, Gilman P. Fear of insurance discrimination is a factor in avoiding genetic testing in women at high risk, for hereditary breast cancer. Proc Lynn Sage Breast Cancer Symposium, 2:A5 (2000).

Tichansky DL, Nesbit M, Lui Z-J, Dabrow MB, Palazzo J, Herlyn M, Sauter ER. FGF-BP expression in clinical and experimental human squamous epithelium. Proc AACR 42:4327 (2001).

DeMoraes E, Flogler W, Grant D, Wahl M, Leeper D, Zrada S, Malin A, Conners S, Fortier AH, Dabrow M, Sidor C, Capizzi RL. Recombinant human angiostatin (rhA): a Phase I clinical trial assessing the safety, pharmacokinetics (PK) and pharmacodynamics (PD). Proc ASCO 20:10 (2001).

Qin W, Zhu W, Hsiung R, Dabrow M, Sauter E. High levels of basic fibroblast growth factor (bFGF) in nipple aspirate fluid (NAF) are associated with breast cancer. Proc AACR 4551 (2002).

Book Chapters:

Dabrow MB, Gabuzda TG. Non-immune hemolysis and toxic methemoglobinemia in Comprehensive Toxicology, ed. Sipes IG, McQueen CA, Gandolfi AJ, Pergamon, Oxford, 1997, Vol 4, p. 59.

Dabrow MB, Gabuzda TG. Acquired hemolytic anemia in Current Diagnosis 9, ed. Conn RB, Borer Wz, Snyder JW, Saunders, Philadelphia, 1997, p. 484.

RESEARCH

2005 - Principal Investigator
Aging and Tolerance to Chemotherapy
Sharpe-Strumia Research Foundation of Bryn Mawr Hospital.

2003-2004 - Principal Investigator
Age as a Factor in Tolerance of Chemotherapy
State of New Jersey Commission on Cancer Research

2002 - Phase II trial of Doxil plus Herceptin in the Treatment of Metastatic Breast Cancer Overexpressing the HER2 protein
UMDNJ-SOM OrthoBiotech

2001-2002 - Phase I study of Adjuvant Sequential Epirubicin, Paclitaxel, Cyclophosphamide in a Dose Dense Manner in High Risk Breast Cancer Patients

Recent Honors, Awards, Citations

2011, 2010, 2009, 2007 - TOP DOCTOR - Oncology/Hematology - Main Line Today Magazine

2003 - "TOP DOC" in Oncology / Hematology
South Jersey Magazine

 

Community/Team Clinical Affiliations

Dr. Dabrow is available as a speaker to community groups. 

Member of American Cancer Society Advisory Board

Manuscript Referee
Cancer, Chemotherapy & Pharmaclogy
American Journal of Obstetrics & Gynecology
The Journal of Reproductive Medicine

Personal Quote

To treat each patient as an individual, and sculpt therapies that match each person's goals and needs.

Statement of Practice Philosophy:

To provide the highest quality treatment possible in a supportive, caring environment, utilizing the most effective and innovative therapies, while focused on each individual's special needs and goals of care.

Current Memberships and Activities

American Osteopathic AssociationAmerican College of Osteopathic InternistsAmerican Association for Cancer Research
American Society of Clinical OncologyAmerican Society of Human Genetics

GENERAL

Specialties: Hematology/Oncology (Board Certified in 1991) - Accepting New Patients
Oncology (Board Certified in 1990) - Accepting New Patients
Internal Medicine (Board Certified in 1990) - Not Accepting New Patients

Age: 56      Gender: M
Years in practice: 23
Main Line HealthCare Physician

Medical School:
Kansas City University of Medicine and Bioscience

Internship:
Detroit Osteopathic Hospital

Residency:
Detroit Osteopathic Hospital

Fellowship:
Fox Chase Cancer Center/Temple University Hospital

Primary Affiliation:  Paoli Hospital

* Members of the Main Line Health medical staff are affiliated with Bryn Mawr Hospital, Lankenau Medical Center, Paoli Hospital and Riddle Hospital.

Titles

Academic Titles:
Adjunct Associate Member, Fox Chase Cancer Center
Associate Member, LIMR

Clinical/Dept Titles:

Medical Director, Cancer Center at Paoli Hospital
Attending Physician


PRACTICE

Practice Name:
Main Line Oncology/Hematology

appointment icon Locations:

Cancer Center of Paoli Hospital
255 West Lancaster Avenue
Paoli, PA  19301
TEL: 484.565.1600 FAX: 610.647.2006
transportation icon Access Information:  Public Transportation,Handicap Access
hours icon Hours: Weekdays
Main Line Health Center at Exton Square
154 Exton Square Parkway
Exton, PA  19341
TEL: 484.565.1600 FAX: 610.647.2006
hours icon Hours: Weekdays
Areas of Clinical Interest: Advanced treatment for all cancer diagnoses, including:
- Breast Cancer
- Senior Oncology
- Gynecological Cancers
- Genitourinary Cancers

Statement of Practice Philosophy

To provide the highest quality treatment possible in a supportive, caring environment, utilizing the most effective and innovative therapies, while focused on each individual's special needs and goals of care.


PUBLICATIONS & CITATIONS

Recent Clinical Studies Published

Wilkins-Childs JC, Dabrow MB, Freed N. Sudden onset of a febrile illness in a female with hemochromatosis. Infect Med 12(3):142-144 (1995).

 

Dabrow MB, Antoniades J. Sequential adjuvant CMF Chemotherapy followed by radiotherapy in the treatment of early-stage breast cancer: The Lankenau Hospital Experience. The Breast Journal 3:15-18 (1997).

Dabrow MB, Francesco MR, McBrearty FX, Caradonna S. Effects of Platelet derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncology 71:29-37 (1998).

Dabrow MB, Francesco MR, Gilman PB, Cantor R, Rose L, Meyer TJ. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastitic non-small cell lung cancer. Cancer Invest 21:517-525 (2003).

Langer CJ, Godfrey S, Richter M, Dabrow M, Rosenblum N. Durable complete remission in recurrent metastatic squamous cell carcinoma of the cervix after treatment with bleomycin, ifosfamide and carboplatin. Proc ASCO 14:796 (1995).

Dabrow MB, Gilman PB, Meyer TJ, Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer. Proc ASCO 18:1930 (1999).

Desnoyers R, Fava T, Dabrow M, Mitchell EP, Weinberg DS, Waldman SA. Guanylyl cyclase C (GCC) is a specific biomarker that may be useful for postoperative surveillance of patients with colorectal cancer. Proc ASCO 19:1005 (2000).

Olander E, Shields N, Gilman P, Olander E, Dickinson S, Atassi S, Mushlin J, Schneider A, Gilman P. The impact of breast cancer risk assessment and education for women at average and moderately increased risk. Proc ASHG 67:377 (2000).

Bardakjian T, Shields N, Gilman P, Olander E, Dickinson S, Atassi S, Mushlin J, Schneider A, Dabrow M. The impact of genetic counseling/testing for breast and ovarian cancer in a free and anonymous community program. Proc ASHG 67:395 (2000)

Atassi S, Dabrow M, Olander E, Bardakjian T, Mushlin J, Shields N, Gilman P. Fear of insurance discrimination is a factor in avoiding genetic testing in women at high risk, for hereditary breast cancer. Proc Lynn Sage Breast Cancer Symposium, 2:A5 (2000).

Tichansky DL, Nesbit M, Lui Z-J, Dabrow MB, Palazzo J, Herlyn M, Sauter ER. FGF-BP expression in clinical and experimental human squamous epithelium. Proc AACR 42:4327 (2001).

DeMoraes E, Flogler W, Grant D, Wahl M, Leeper D, Zrada S, Malin A, Conners S, Fortier AH, Dabrow M, Sidor C, Capizzi RL. Recombinant human angiostatin (rhA): a Phase I clinical trial assessing the safety, pharmacokinetics (PK) and pharmacodynamics (PD). Proc ASCO 20:10 (2001).

Qin W, Zhu W, Hsiung R, Dabrow M, Sauter E. High levels of basic fibroblast growth factor (bFGF) in nipple aspirate fluid (NAF) are associated with breast cancer. Proc AACR 4551 (2002).

Book Chapters:

Dabrow MB, Gabuzda TG. Non-immune hemolysis and toxic methemoglobinemia in Comprehensive Toxicology, ed. Sipes IG, McQueen CA, Gandolfi AJ, Pergamon, Oxford, 1997, Vol 4, p. 59.

Dabrow MB, Gabuzda TG. Acquired hemolytic anemia in Current Diagnosis 9, ed. Conn RB, Borer Wz, Snyder JW, Saunders, Philadelphia, 1997, p. 484.

RESEARCH

2005 - Principal Investigator
Aging and Tolerance to Chemotherapy
Sharpe-Strumia Research Foundation of Bryn Mawr Hospital.

2003-2004 - Principal Investigator
Age as a Factor in Tolerance of Chemotherapy
State of New Jersey Commission on Cancer Research

2002 - Phase II trial of Doxil plus Herceptin in the Treatment of Metastatic Breast Cancer Overexpressing the HER2 protein
UMDNJ-SOM OrthoBiotech

2001-2002 - Phase I study of Adjuvant Sequential Epirubicin, Paclitaxel, Cyclophosphamide in a Dose Dense Manner in High Risk Breast Cancer Patients

Recent Honors, Awards, Citations

2011, 2010, 2009, 2007 - TOP DOCTOR - Oncology/Hematology - Main Line Today Magazine

2003 - "TOP DOC" in Oncology / Hematology
South Jersey Magazine

 

Community/Team Clinical Affiliations

Dr. Dabrow is available as a speaker to community groups. 

Member of American Cancer Society Advisory Board

Manuscript Referee
Cancer, Chemotherapy & Pharmaclogy
American Journal of Obstetrics & Gynecology
The Journal of Reproductive Medicine

Personal Quote

To treat each patient as an individual, and sculpt therapies that match each person's goals and needs.

Statement of Practice Philosophy:

To provide the highest quality treatment possible in a supportive, caring environment, utilizing the most effective and innovative therapies, while focused on each individual's special needs and goals of care.

Current Memberships and Activities

American Osteopathic AssociationAmerican College of Osteopathic InternistsAmerican Association for Cancer Research
American Society of Clinical OncologyAmerican Society of Human Genetics

Membership on the medical staff of any of our hospitals does not constitute an employment or agency relationship.

Compare Physicians
  •  

Connect with MLH

New Appointments
1.866.CALL.MLH

 Well Ahead Newsletter


Connect With MLH

Copyright 2014 Main Line Health

Printed from: www.mainlinehealth.org/phy/Page.asp?PageID=PHY005903

The information provided in this Web site is for informational purposes only. It is not a substitute for medical advice. All medical information presented should be discussed with your healthcare professional. See additional Terms of Use at www.mainlinehealth.org/terms. For more information, call 1.866.CALL.MLH.